Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Mauriac

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Bulletin Du Cancer|March 13, 2002
[Standards, Options and Recommendations for non metastatic breast cancer patients]Louis Mauriac
Seminars in Oncology|September 27, 2003
Aromatase inhibitors in early breast cancer treatmentLouis Mauriac, Ian Smith
Breast (Edinburgh, Scotland)|September 20, 2005
When will more useful predictive factors be ready for use?Louis Mauriac, Marc Debled, Gaëtan MacGrogan
Breast Cancer Research and Treatment|November 26, 2008
Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trialLouis Mauriac, Gilles Romieu, José Bines
Lancet (London, England)|January 17, 2004
Spreading the word, but not too thinlyAnthony Howell, C Kent Osborne, Louis Mauriac
Bulletin Du Cancer|June 4, 2011
[Medical treatments of endocrine-sensitive Her-2 negative breast cancers: a review]Marc Debled, Florence Dalenc, Louis Mauriac, et al.
Bulletin Du Cancer|November 1, 2006
[HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?]Yazid Belkacémi, Joseph Gligorov, Louis Mauriac, et al.
Cancer|February 21, 2008
Distinction between isolated tumor cells and micrometastases in breast cancer: is it reliable and useful?Isabelle de Mascarel, Gaetan MacGrogan, Marc Debled, et al.
Journal of the National Cancer Institute|January 1, 2010
Re: Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancerMarc Debled, Isabelle de Mascarel, Veronique Brouste, et al.
Cancer|April 24, 2007
Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysisMarc Debled, Gaëtan MacGrogan, Véronique Brouste, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Bulletin Du Cancer|March 13, 2002
[Standards, Options and Recommendations for non metastatic breast cancer patients]Louis Mauriac
Seminars in Oncology|September 27, 2003
Aromatase inhibitors in early breast cancer treatmentLouis Mauriac, Ian Smith
Breast (Edinburgh, Scotland)|September 20, 2005
When will more useful predictive factors be ready for use?Louis Mauriac, Marc Debled, Gaëtan MacGrogan
Breast Cancer Research and Treatment|November 26, 2008
Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trialLouis Mauriac, Gilles Romieu, José Bines
Lancet (London, England)|January 17, 2004
Spreading the word, but not too thinlyAnthony Howell, C Kent Osborne, Louis Mauriac
Bulletin Du Cancer|June 4, 2011
[Medical treatments of endocrine-sensitive Her-2 negative breast cancers: a review]Marc Debled, Florence Dalenc, Louis Mauriac, et al.
Bulletin Du Cancer|November 1, 2006
[HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?]Yazid Belkacémi, Joseph Gligorov, Louis Mauriac, et al.
Cancer|February 21, 2008
Distinction between isolated tumor cells and micrometastases in breast cancer: is it reliable and useful?Isabelle de Mascarel, Gaetan MacGrogan, Marc Debled, et al.
Journal of the National Cancer Institute|January 1, 2010
Re: Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancerMarc Debled, Isabelle de Mascarel, Veronique Brouste, et al.
Cancer|April 24, 2007
Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysisMarc Debled, Gaëtan MacGrogan, Véronique Brouste, et al.
Pageof 6